DSNK.Y Stock Overview
Manufactures, markets, and sells pharmaceutical products worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for DSNK.Y from our risk checks.
Daiichi Sankyo Company, Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥35.39 |
| 52 Week High | JP¥37.57 |
| 52 Week Low | JP¥23.72 |
| Beta | 0.26 |
| 1 Month Change | 5.44% |
| 3 Month Change | 5.96% |
| 1 Year Change | 3.51% |
| 3 Year Change | 57.96% |
| 5 Year Change | 87.13% |
| Change since IPO | 469.28% |
Recent News & Updates
Recent updates
Shareholder Returns
| DSNK.Y | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 2.2% | -0.8% | -1.2% |
| 1Y | 3.5% | 14.8% | 21.5% |
Return vs Industry: DSNK.Y underperformed the US Pharmaceuticals industry which returned 14.8% over the past year.
Return vs Market: DSNK.Y underperformed the US Market which returned 21.5% over the past year.
Price Volatility
| DSNK.Y volatility | |
|---|---|
| DSNK.Y Average Weekly Movement | 4.1% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: DSNK.Y has not had significant price volatility in the past 3 months.
Volatility Over Time: DSNK.Y's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1899 | 17,435 | Sunao Manabe | www.daiichisankyo.com |
Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol.
Daiichi Sankyo Company, Limited Fundamentals Summary
| DSNK.Y fundamental statistics | |
|---|---|
| Market cap | US$67.99b |
| Earnings (TTM) | US$1.28b |
| Revenue (TTM) | US$10.18b |
53.3x
P/E Ratio6.7x
P/S RatioIs DSNK.Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DSNK.Y income statement (TTM) | |
|---|---|
| Revenue | JP¥1.60t |
| Cost of Revenue | JP¥415.32b |
| Gross Profit | JP¥1.19t |
| Other Expenses | JP¥985.64b |
| Earnings | JP¥200.73b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 104.71 |
| Gross Margin | 74.07% |
| Net Profit Margin | 12.53% |
| Debt/Equity Ratio | 6.0% |
How did DSNK.Y perform over the long term?
See historical performance and comparison